A lifesaving medication that reverses opioid overdoses will soon become more accessible, thanks to an innovative nonprofit company. Harm Reduction Therapeutics has received FDA approval for RiVive, the first over-the-counter naloxone nasal spray created by a nonprofit.

Available in early 2024, RiVive aims to save lives by providing broad, low-cost access to this critical drug. Unlike big pharma, Harm Reduction Therapeutics is focused on equipping hardest-hit communities – not profits. At least 200,000 doses will be distributed free of charge where they are needed most.

This creative approach could be a game-changer in expanding access to naloxone, a medication that can mean the difference between life and death for those experiencing an opioid overdose. Harm Reduction Therapeutics exemplifies the power of nonprofits to drive real change.

Read more ➝

Elon Musk blames Anti-Defamation League for ad sales slump, threatens lawsuit  | Axios 

More schools that forced American Indian children to assimilate revealed  |  Washington Post

Worker defrauds Massachusetts nonprofit out of $100,000 worth of Apple laptops, officials say  | WCVB Boston